- Home
- COSM vs BIVI Comparison
COSM vs BIVI Comparison
Compare COSM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- BIVI
- Stock Information
- Founded
- COSM 2009
- BIVI 2013
- Country
- COSM Greece
- BIVI United States
- Employees
- COSM N/A
- BIVI N/A
- Industry
- COSM Other Pharmaceuticals
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- COSM Health Care
- BIVI Health Care
- Exchange
- COSM Nasdaq
- BIVI Nasdaq
- Market Cap
- COSM 8.2M
- BIVI 15.1M
- IPO Year
- COSM 2013
- BIVI N/A
- Fundamental
- Price
- COSM $0.43
- BIVI $1.23
- Analyst Decision
- COSM
- BIVI Strong Buy
- Analyst Count
- COSM 0
- BIVI 1
- Target Price
- COSM N/A
- BIVI $30.00
- AVG Volume (30 Days)
- COSM 749.7K
- BIVI 757.2K
- Earning Date
- COSM 04-16-2025
- BIVI 05-13-2025
- Dividend Yield
- COSM N/A
- BIVI N/A
- EPS Growth
- COSM N/A
- BIVI N/A
- EPS
- COSM N/A
- BIVI N/A
- Revenue
- COSM $54,426,402.00
- BIVI N/A
- Revenue This Year
- COSM $28.14
- BIVI N/A
- Revenue Next Year
- COSM N/A
- BIVI N/A
- P/E Ratio
- COSM N/A
- BIVI N/A
- Revenue Growth
- COSM 1.97
- BIVI N/A
- 52 Week Low
- COSM $0.28
- BIVI $0.62
- 52 Week High
- COSM $1.58
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- COSM 52.13
- BIVI 63.09
- Support Level
- COSM $0.40
- BIVI $1.04
- Resistance Level
- COSM $0.55
- BIVI $1.29
- Average True Range (ATR)
- COSM 0.06
- BIVI 0.13
- MACD
- COSM 0.01
- BIVI 0.06
- Stochastic Oscillator
- COSM 56.06
- BIVI 83.64
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.